兆科眼科-B(06622)：用于治疗儿童近视加深的NVK002为期两年的中国第III期临床试验(CHINA CHAMP)的积极顶线结果

智通财经10-23

智通财经APP讯，兆科眼科-B(06622)发布公告，NVK002(公司核心产品之一)为期两年的第III期临床试验的顶线结果。经过两年的治疗，这项研究分析显示，NVK002滴眼液组(0.01%和0.02%剂量)对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。China CHAMP是一项随机、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2477306338?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-23 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477306338","market":"hk","top_or_hot":-1,"title":"兆科眼科-B(06622)：用于治疗儿童近视加深的NVK002为期两年的中国第III期临床试验(CHINA CHAMP)的积极顶线结果","media":"智通财经","content":"<div>\n<p>智通财经APP讯，兆科眼科-B(06622)发布公告，NVK002(公司核心产品之一)为期两年的第III期临床试验的顶线结果。经过两年的治疗，这项研究分析显示，NVK002滴眼液组(0.01%和0.02%剂量)对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。China CHAMP是一项随机、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1198122.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>兆科眼科-B(06622)：用于治疗儿童近视加深的NVK002为期两年的中国第III期临床试验(CHINA CHAMP)的积极顶线结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n兆科眼科-B(06622)：用于治疗儿童近视加深的NVK002为期两年的中国第III期临床试验(CHINA CHAMP)的积极顶线结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-23 17:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1198122.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，兆科眼科-B(06622)发布公告，NVK002(公司核心产品之一)为期两年的第III期临床试验的顶线结果。经过两年的治疗，这项研究分析显示，NVK002滴眼液组(0.01%和0.02%剂量)对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。China CHAMP是一项随机、...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1198122.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1198122.html","article_id":"2477306338","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477306338","pubTimestamp":1729676818,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，兆科眼科-B 发布公告，NVK002为期两年的第III期临床试验的顶线结果。经过两年的治疗，这项研究分析显示，NVK002滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。该项试验涉及18间中心，入组777名患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","BK1583":"高瓴概念","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK1574":"生物医药B类股","BK4134":"信息科技咨询与其它服务","03347":"泰格医药","III":"信息服务","06622":"兆科眼科-B","BK1191":"制药"},"translate_title":"Zhaoke Ophthalmology-B (06622): Positive top-line results of the two-year China Phase III clinical trial (CHINA CHAMP) of NVK002 for the treatment of deepening myopia in children","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"06622":1,"III":1},"content_text":"智通财经APP讯，兆科眼科-B(06622)发布公告，NVK002(公司核心产品之一)为期两年的第III期临床试验的顶线结果。经过两年的治疗，这项研究分析显示，NVK002滴眼液组(0.01%和0.02%剂量)对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，NVK002滴眼液组优于安慰剂组，且具有剂量依赖。两种剂量的NVK002安全性良好，患者使用依从性好。China CHAMP是一项随机、双盲、安慰剂平行对照、多中心、第III期临床研究，其主要目标为评估NVK002(0.01%及0.02%的低剂量阿托品)对治疗中国儿童及青少年近视加深的疗效及安全性。该项试验涉及18间中心，入组777名患者。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477306338"}